The comparative efficacy of SGLT-2 inhibitors and GLP-1 receptor agonists on metabolic benefits in T2DM patients: a systematic review and network meta-analysis | Synapse

⌘+K

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Comparative Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Versus Glucagon-Like Peptide-1 (GLP-1) Agonists on Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Network Meta-Analysismeta-analysis · 2026 · 4 citations
2Comparative Safety of SGLT2 Versus DPP4 Inhibitors in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled TrialsSystematic Review · 2026
3Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trialsmeta-analysis · 2021 · 679 citations
4Network and pairwise meta-analysis of the effects of novel hypoglycemic agents on cardiorenal outcomes in patients with type 2 diabetes and heart failureMeta-Analysis · 2026
5CARDIOVASCULAR OUTCOMES IN DIABETIC PATIENTS TREATED WITH SGLT2I AND GLP1–RA: SYSTEMATIC REVIEW AND META–ANALYSISmeta-analysis · 2025

More related papers

More from European journal of medical research

Association of microcirculatory resistance index based on single-view coronary angiography with 1-year composite clinical outcome in patients with INOCA: an exploratory prospective cohort studySat,
Building a prediction model for nasopharyngeal carcinoma based on machine learning using laboratory test indicators: a study targeting populations in high-risk areasThu,